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The burden of non-TB lung disease presenting to TB clinics in 
The Gambia: preliminary data in the Xpert® MTB/Rif era
S. Jayasooriya,1,2 A. Jobe,1 S. Badjie,1 O. Owolabi,1 A. Rachow,3 J. Sutherland,1 B. Kampmann1,4
A leading cause of mortality related to non-com-municable diseases (NCDs) is chronic respiratory 
disease, which is estimated to have caused 3.8 million 
deaths in 2015.1 While tuberculosis (TB) remains a 
major problem, in some low- and middle-income 
countries (LMICs), only 10–20% of patients presenting 
with a persistent cough have TB.2 There is thus a large 
proportion of patients with respiratory symptoms of 
unknown aetiology.
The advent of the Xpert® MTB/RIF (Cepheid, 
Sunnyvale, CA, USA), a nucleic-acid amplification test, 
has led to earlier diagnoses as same-day results are 
now possible.3 Xpert has a sensitivity of 89% com-
pared to sputum culture, the gold standard; impor-
tantly, this increased sensitivity means that those who 
test negative are less likely to have active TB.
TB clinics have been ill equipped, both in terms of 
staff experience and equipment, to effectively diag-
nose and treat other respiratory diseases, despite the 
WHO strategy highlighting the Practical Approach to 
Lung Health (PAL).4 We generated preliminary data in 
The Gambia on the potential of TB platforms to cap-
ture, investigate and manage chronic respiratory 
symptoms in patients classified as not having TB.
MATERIALS AND METHODS
We prospectively recruited all patients from a TB re-
search clinic who did not meet the inclusion criteria 
(at least one sputum sample positive for TB on Xpert) 
for the TB Sequel Project, a study exploring the impact 
of TB on lung function.5 All patients underwent a 
chest radiograph and rapid human immunodeficiency 
virus (HIV) testing (Alere Determine™ HIV-1/2 Ab/Ag; 
Abbott Laboratories, Chicago, IL, USA), with labora-
tory serology confirmation if positive (4th generation 
Liaison XL Murex HIV Ab/Ag assay [DiaSorin, Salug-
gia, Italy];6 Hexagon HIV1/2 [HUMAN Diagnostics, 
Wiesbaden, Germany]; Geenius HIV-1/2 confirmation 
assay [Bio-Rad, Hercules, CA, USA]) and investigations 
as clinically indicated (e.g., full blood count, urea and 
electrolytes, liver function tests, electrocardiogram, 
echocardiography, pleural aspirate, peak expiratory 
flow rate, sputum TB culture and/or microbiology). All 
patients had a minimum of 2- and 4-week follow-ups; 
the number of follow-up visits was increased accord-
ing to clinical need. Asthma diagnosis was based on 
peak expiratory flow rate diary in patients presenting 
with audible wheeze and a history of more than three 
symptomatic episodes annually. Diagnoses of bacterial 
pneumonia were based on suggestive clinical features 
and chest radiograph infiltrates that resolved follow-
ing antibiotic treatment. Heart failure was based on 
consistent clinical features and echocardiography (re-
duced ejection fraction, 50%). Serial renal function 
testing results of estimated glomerular filtration rate 
15 ml/min/1.73m2 were classified chronic renal 
failure.
Ethical Approval
Ethical approval for TB Sequel was obtained from the 
Medical Research Council (MRC), London, UK, and The 
Gambia Government/MRC Joint Ethics Committee. 
Written consent was provided by study participants.
RESULTS
Between September 2017 and July 2018, 239 patients 
with chronic cough (2 weeks) and any of the follow-
ing symptoms—night sweats, fever, weight loss, mal-
aise or chest pain—were screened for TB. Of those who 
fulfilled the inclusion criteria for TB Sequel, 114 pa-
tients had Xpert-positive sputum results. The remain-
ing 125 (52.3%) were Xpert- (n = 63, 50.4%) or 
Xpert-Ultra- (n = 62, 49.6%) negative on spot and 
early morning sputum samples (routine use of 
Xpert-Ultra was implemented in clinic mid-study). Of 
these 125 patients, 17 were classified as TB on clinical 
and radiological grounds (Table 1). The remaining 108 
(45.1%) were classified as not having TB. Not TB pa-
tients were significantly older, heavier, less likely to be 
male and less likely to smoke than TB patients (de-
fined as those who were sputum Xpert-positive (bacte-
riologically confirmed) and Xpert-negative (clinically 
diagnosed) patients (Table 1). 
There were four deaths and six LTFU among the 
108 (45.1%) ‘non-TB’ patients included. Of these, 55% 
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In some low and middle-income countries, 10–20% of 
patients presenting with a persistent cough have tuber-
culosis (TB). Once TB is excluded, health service provision 
for alternative diagnoses is limited. We prospectively 
studied patients with two Xpert-negative sputum results 
presenting to a TB clinic in The Gambia. Of 239 patients, 
108 did not have TB; 65/102 (6 were lost to follow-up) 
had alternative diagnoses, 24.6% of which were non-re-
spiratory; 37/102 had no diagnosis, 27.0% of whom 
were HIV-1-positive; 37.8% had a history of TB and 
24.3% smoked. We highlight the need for general health 
service integration with TB platforms and exploration of 
non-TB patients with chronic respiratory symptoms.
Burden of non-TB lung disease in TB clinics 167Public Health Action
(60/108) received antibiotics (non-fluoroquinolone) for presumed 
bacterial infections, providing a future target for community anti-
microbial stewardship. Excluding LTFU, none of the 102 devel-
oped clinical or radiological signs of TB during a median fol-
low-up period of 2 months (range 1–6 months). Diagnoses were 
established in 65/102 (63.7%) non-TB patients (Table 2). The ma-
jority of these were acute respiratory conditions (75.3%), followed 
by cardiovascular (20%) and renal disease (3.1%), and one patient 
(1.5%) with presumed haematological malignancy (Table 2).
The proportions of HIV-1-infected patients in the Xpert-posi-
tive group (n = 114), Xpert-negative, clinically diagnosed group (n 
= 17) and the non-TB group (n = 108) were respectively 8.7%, 
41.2% and 11.1%. The HIV positivity rate did not significantly 
differ between the sputum Xpert-positive TB patients and the 
non-TB patients.
The diagnosis in 37/102 (36.3%) not-TB cases remained un-
known. A high proportion of these (10/37, 27.0%) were new 
HIV-1 diagnoses, 14/37 (37.8%) had a past history of TB and 9/37 
(24.3%) smoked.
DISCUSSION
Using limited in-country diagnostics, nearly half of all patients 
presenting to a TB clinic did not have a final diagnosis of TB, and 
36% had no alternative diagnosis. Of these, many were HIV-1 
positive, and had past histories of TB and smoking, providing in-
sights into potential disease aetiology. While the differential in-
cludes infections such as non-tuberculous mycobacteria (NTM) 
and chronic pulmonary aspergillosis (CPA),7 it is likely that many 
represent NCDs, e.g., chronic obstructive pulmonary disease 
(COPD) or bronchiectasis. Better radiology (e.g., computed to-
mography scans) and pathogen diagnostic facilities8 in future 
studies should aim to characterise this group further. As data from 
Asia highlight, occupational and environmental air pollutants 
should also be taken in to account.9
The HIV-1 positivity rate in the non-TB group was seven-fold 
higher than the estimated population rate in The Gambia 
(1.6%).10 This is a striking finding in patients who not only do 
not have TB, but also lack other obvious HIV-associated opportu-
nistic infections (e.g., acute bacterial pneumonia). As our findings 
are based on secondary care, these may not be representative of 
community rates, but do support the WHO recommendation to 
offer HIV testing to all patients with suspected TB, and not just 
those with confirmed TB. This is important, even in countries 
with relatively low TB prevalence, such as The Gambia.
As our study was pragmatically performed in the context of 
routinely available care in The Gambia, it has a number of limita-
tions. More sophisticated diagnostics were unavailable (for exam-
ple, formal diagnoses of COPD were not possible). Routine culture 
of smear-negative TB patients is not standard practice in TB pro-
grammes in The Gambia, and it was only possible to perform cul-
ture on 24 non-TB participants due to resource constraints. Al-
though no one in this group developed active TB, it is possible 
that some patients may have had NTM lung disease or developed 
active TB post follow-up.
Even after a decade of PAL strategy, services offered to non-TB 
patients with chronic respiratory symptoms remain in their in-
fancy in sub-Saharan Africa. As efforts are enhanced to find and 
treat TB using highly sensitive assays, the opportunity to build 
NCD pathways integrated into TB platforms still exists. These pre-












TB vs. not TB
P value*
Age, years, median [IQR] 32 [26–40] 42 [35–52] 40 [28–47] 0.0331
Male:female ratio 2.5:1 2.2:1 1:1 0.0087
HIV-1-positive 10 (8.7) 7 (41.2) 12 (11.1) NS†
Weight, kg, median [IQR] 51 [46–58] 51 [43–58] 56 [49–64] 0.0015
Former or current smoker 46 (40.4) 5 (29.4) 24 (22.2) 0.0091
Past history of TB 7 (6.1) 5 (29.4) 16 (14.8) NS†
Deaths 2 (1.8) 0 4 (3.7) NS†
* Calculated using Mann-Whitney U statistical comparison of unmatched pairs or χ2 (and Fisher’s exact) test as indicated.
† Not significant at threshold of P = 0.05.
TB = tuberculosis; IQR = interquartile range; HIV = human immunodeficiency virus.










HIV-1-positive 10 (27.0) 2 (3.1)
Past history of TB 14 (37.8) 2 (3.1)
Former or current smoker 9 (24.3) 15 (23.0)
Deaths
 Cause unknown 2 (5.4) —
 Presumed lung malignancy — 1 (1.5)
 Haematological malignancy — 1 (1.5)
Respiratory
 Other bacterial or viral 
respiratory tract infection — 32 (49.2)
 Pneumonia — 8 (12.3)
 Asthma — 4 (6.2)
 Pleural effusion — 2 (3.1)
 Lung abscess — 1 (1.5)
 Lung malignancy — 1 (1.5)
Cardiovascular
 Heart failure — 10 (15.4)
 Structural heart disease — 2 (3.1)
 Ischaemic heart disease — 1 (1.5)
Renal
 Chronic renal failure — 2 (3.1)
* Patients lost to follow-up have been excluded.
HIV = human immunodeficiency virus; TB = tuberculosis.
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liminary findings suggest that further context-specific implemen-
tation research focusing on non-TB screen-outs is needed to en-
able application of the PAL strategy.
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Dans certains pays à revenu faible et moyen, 10–20% des patients se 
présentant avec une toux persistante ont une tuberculose (TB). Une 
fois que la TB est exclue, la prise en charge des diagnostics alternatifs 
est limitée. Nous avons étudié de façon prospective les patients ayant 
eu deux tests de crachats négatifs à l’Xpert® MTB/RIF se présentant à 
un dispensaire TB en Gambie. Des 239 patients, 108 n’avaient pas de 
TB ; 65/102 (6 perdus de vue) ont eu un autre diagnostic (non 
respiratoire dans 24,6% des cas) ; 37/102 n’ont pas eu de diagnostic, 
dont 27,0% ont été positifs à l’infection par le virus de 
l’immunodéficience humaine 1, 37,8% avaient des antécédents de 
TB et 24,3% fumaient. Nous mettons l’accent sur le besoin 
d’intégration générale des services de santé avec des plateformes TB 
et une exploration des patients non TB ayant des symptômes 
respiratoires chroniques.
En algunos países de recursos bajos y medianos, 10–20% de 
pacientes que acuden a la consulta con tos persistente presentan 
tuberculosis (TB). Una vez que se ha excluido el diagnóstico de 
TB, la provisión de servicios de salud para otras afecciones es 
escasa. En el presente estudio se analizaron de manera prospectiva 
los pacientes con dos resultados negativos de la prueba Xpert® 
MTB/RIF en muestras de esputo, que acudían a un consultorio de 
TB en Gambia. Ciento ocho de los 239 pacientes no presentaban 
TB. En 65 de 102 pacientes (seis perdidos durante el seguimiento) 
se definió un diagnóstico diferente de TB y en 24,6% de los casos 
se trataba de una afección no respiratoria. En 37 de los 102 
pacientes no se formuló un diagnóstico y de estos el 27,0% eran 
positivos frente al virus de la inmunodeficiencia humana, 37,8% 
tenían antecedente de TB y 24,3% eran fumadores. Los resultados 
del estudio destacan la necesidad de integrar los servicios 
generales de salud con las plataformas de atención de la TB y de 
explorar a los pacientes con síntomas respiratorios crónicos que 
no presentan TB.
